PBMs & 2026 Reform

What this guide covers

PBMs & 2026 Reform explains pharmacy benefit managers—the companies most patients never name, but that often decide whether a prescription is covered and how much it costs. It is written for beginner patient advocates helping someone at the pharmacy counter or on hold with "pharmacy benefits."

You do not need to master antitrust law. You need a clear map: who is in the middle, why rules like prior authorization exist, why prices feel irrational, and what federal action in 2026 is trying to change.

Start with Prescription Coverage Basics for copays and reject codes. Use this guide when you want the system behind those rejects.

This is educational information, not legal or financial advice. Laws and settlements evolve—verify dates on official sources below.

Why advocates should know PBMs

When a fill fails, families often blame the pharmacist, the doctor's office, or "insurance" as one blob. In practice, the pharmacy claim usually runs through a PBM. The PBM applies the formulary, quantity limits, step therapy, and prior authorization rules you fight in other guides.

Calling the number on the insurance card for prescriptions often reaches the PBM or its subcontractor—not the same team that handled the hospital bill. Knowing that role stops advocates from using the wrong appeal path (medical instead of Rx) and sets realistic expectations. Many fixes are prescriber paperwork plus a PBM portal, not arguing at retail checkout.

What a PBM is

A pharmacy benefit manager (PBM) administers the prescription drug benefit for insurers, employers, Medicare Part D plans, and many Medicaid managed care plans.

Large PBMs you may see on cards or reject screens include CVS Caremark, Express Scripts (ESI), Optum Rx, Humana Pharmacy Solutions, and others. They commonly publish or implement the formulary, process claims at the pharmacy, operate or steer to mail-order and specialty pharmacies, run prior authorization and step therapy programs, and negotiate rebates with drug manufacturers.

What happens when you fill a Rx

The prescriber sends the prescription to the pharmacy. The pharmacy enters the drug and the patient's Rx BIN, PCN, and Group—the pharmacy benefit ID numbers on the card. The claim goes to the PBM, not straight to the medical insurer. The PBM returns pay or reject, with a copay amount or a reject code. The patient pays the copay; the pharmacy receives reimbursement from the PBM.

Behind that single copay are larger money flows—plan premiums, manufacturer rebates, pharmacy reimbursement—that patients rarely see. The PBM sits in the middle of who gets paid and which drug is favored on the formulary.

What PBMs control

Formulary, PA & step therapy

The PBM, with the plan, sets which drugs are covered and which hurdles apply. That is why advocates use Formularies & Drug Tiers, Rx Prior Authorization, and Step Therapy—you are navigating PBM-administered rules.

Pharmacy networks

PBMs contract with preferred retail chains, mail-order pharmacies, and specialty pharmacies. A fill at a non-preferred pharmacy can cost more or reject—even if the drug is on formulary.

What you pay at the counter

The PBM adjudication sets copay or coinsurance for that fill. High coinsurance on a high list price is a common advocate pain point, especially on specialty tiers.

How PBMs make money (plain language)

PBMs are businesses. Their revenue models can pull in a different direction than a patient trying to minimize out-of-pocket cost. Advocates hear the effects; they rarely see the spreadsheets.

Rebates

Manufacturers often pay rebates after a drug is used. Larger rebates on higher-list drugs can influence which products get favorable formulary placement. Critics argue that structure can keep list prices high even when net plan costs differ.

Spread pricing

In some contracts, the PBM charges the plan more than it pays the pharmacy and keeps the difference—"spread." Patients do not see spread directly, but it feeds fights over plan costs and pharmacy closures.

Why list prices look so high

A patient with coinsurancemay pay a percent of list price, not the plan's net price after rebates. Manufacturer copay cardson expensive brands can shrink insured patients' counter cost while list price stays high—often with no help for uninsured patients facing cash prices.

Controversies advocates hear about

On insulin, federal investigators have alleged PBMs favored higher-rebate products over lower-priced options; the FTC sued major PBMs in 2024. List prices rose for many years while affordability remained a crisis for patients.

An FTC interim staff report on PBMs described large markups on some specialty generics at affiliated pharmacies, among other findings. That context helps when a specialty fill price shocks a family.

Independent pharmacies often report low PBM reimbursement and steering to PBM-owned mail or retail networks. These stories explain anger at the system. They do not replace reading the patient's own denial notice and formulary.

2026 reform & enforcement

Federal policymakers and agencies increased PBM scrutiny into 2026. Advocates should know the headlines—implementation dates and patient impact vary by plan type.

FTC enforcement

On February 4, 2026, the FTC announced a settlement with Express Scripts and affiliates aimed at expanding access to lower-priced medicines (including insulin) on affected formularies and changing financial incentives so higher-priced drugs are less favored. Details are in the agency press release linked below.

Federal law changes

The 2026 Consolidated Appropriations Act includes major PBM-related provisions. For Medicare Part D, starting in 2028, direction to compensate PBMs through bona fide service fees rather than compensation tied to drug price—often called rebate delinking. Many employer-sponsored plans must require PBMs to pass rebates through to the health plan at 100%. For Medicare Part D again, starting in 2029, direction to broaden pharmacy participation and limit exclusive steering to affiliated pharmacies—often called any willing pharmacy.

Summaries from benefits counsel can help employers and Medicare specialists. Advocates should still work the patient's current plan rules first.

What may change for patients

Near term, enforcement settlements may shift specific formularies—for example insulin choices on Express Scripts plans. Medium term, Part D and employer markets may see more rebate transparency and pharmacy access if rules are implemented as written.

Do not tell a patient a 2028 or 2029 law already fixed today's reject—that sets false hope. Do explain that systemic pressure is real and their individual case still needs Rx prior authorization, exceptions, or appeals now.

What advocates can do today

Identify the PBM

Check the insurance card for the Rx customer service number and Rx BIN. Read the reject printout or portal message—it may name Caremark, Express Scripts, Optum, or another brand. The employer benefits booklet often lists the "pharmacy benefit administrator."

Practical steps on a case

First, confirm the problem is a pharmacy benefit issue, not a medical prior authorization or a hospital bill. Look up the drug on the plan formulary for tier, prior authorization, step therapy, and quantity limits. Route clinical fixes to the prescriber—prior authorization, step override, corrected quantity. Call the Rx number on the card and log reference numbers.

If the plan still denies coverage, use Denied Prescriptions and program-specific Medicare or Medicaid guides. For affordability tonight, use Medication Affordability—reform does not remove the need for a bridge supply.

Scenarios beginners run into

Plan says call Caremark / Optum / ESI

That is the PBM brand. Use Rx guides, not the medical appeals team. Medical prior authorization approval does not carry over to the pharmacy benefit.

Coinsurance on expensive brand

List price drives the patient's share. Ask about a tiering exception, a formulary alternative, manufacturer assistance, or Low Income Subsidy for Medicare. PBM reform does not instantly lower tonight's copay.

Copay card helps insured, not uninsured

Manufacturer coupons often require commercial insurance and exclude Medicare and Medicaid. Uninsured patients need different resources—340B clinics, assistance foundations, state programs.

Independent pharmacy loses money

The pharmacy may ask the patient to transfer to a chain in the PBM network. Check the preferred pharmacy list before blaming the pharmacist for "not trying."

Insulin brand on formulary only

The formulary may favor one insulin with rebate history. The prescriber may switch to a covered product or document an exception. 2026 enforcement may expand lower-priced options on some Express Scripts formularies—check the current formulary, not news headlines alone.

Patient asks if 2026 law fixed it yet

Explain phased dates—several Part D provisions land in 2028 and 2029. File the prior authorization or exception for the fill due this week.

Related guides

Prescription Coverage Basics, Formularies & Drug Tiers, Rx Prior Authorization, Denied Prescriptions, Specialty Pharmacy, and Medicare Part D Drug Appeals.

Official resources

FTC — Express Scripts settlement (February 4, 2026). FTC — Interim staff report on PBMs. FTC — Express Scripts / insulin proceeding materials. Medicare.gov — Part D drug coverage. Hall Render — Overview of 2026 federal PBM reforms (benefits counsel summary).

For a longer narrative on the same topics (including a drug/money flow diagram), see PBMs, Controversial Practices, and Efforts to Reform in 2026 on GuideMyClaim.com.